Last reviewed · How we verify
Relugolix CT
Relugolix CT works by inhibiting the activity of gonadotropin-releasing hormone (GnRH) receptors.
Relugolix CT works by inhibiting the activity of gonadotropin-releasing hormone (GnRH) receptors. Used for Metastatic castration-resistant prostate cancer.
At a glance
| Generic name | Relugolix CT |
|---|---|
| Also known as | Myfembree |
| Sponsor | University of Michigan |
| Drug class | GnRH receptor antagonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to GnRH receptors, relugolix CT reduces the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to a decrease in testosterone levels. This mechanism is particularly useful in the treatment of prostate cancer.
Approved indications
- Metastatic castration-resistant prostate cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Headache
Key clinical trials
- Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial (PHASE2)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (PHASE3)
- Relugolix for Endometriosis Associated Pain
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial (PHASE3)
- Estradiol-mediated Inflammation and Central Sensitization in the Pathophysiology of Endometriosis-associated Pelvic Pain (PHASE3)
- Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Relugolix CT CI brief — competitive landscape report
- Relugolix CT updates RSS · CI watch RSS
- University of Michigan portfolio CI